Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-10-2020 | Breast Cancer | Epidemiology

Sarcoma of the breast: breast cancer history as etiologic and prognostic factor—A population-based case–control study

Authors: Fredrik Karlsson, Fredrik Granath, Karin E. Smedby, Jan Zedenius, Robert Bränström, Inga-Lena Nilsson

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

Sarcomas of the breast account for about 1% of all breast malignancies. The aim of this national survey was to explore etiologic and prognostic factors.

Methods

Utilizing national Swedish registers, all patients registered with mesenchymal tumors in the breast during the period 1993–2013 (n = 344) were identified and compared to up to ten age and gender matched controls. Cancer history was retrieved for cases and controls. Conditional Poisson regression models were used for calculation of odds ratios.

Results

Previous breast cancer was overrepresented among patients with angiosarcoma. The highest risk occurred ≥ 5 years after treatment for breast cancer (OR 73.9, 95% confidence interval, CI, 25.4–215; P < 0.001). An increase in incidence of angiosarcoma was observed during the study period (1.10, 95% CI 1.05–1.16; P < 0.001). The overall incidence of breast sarcoma increased from 1.52 to 2.04 cases per million per year. Angiosarcoma of the breast was associated with a significant excess mortality compared to age-matched controls (HR 4.65, 95% CI 3.01–7.19; P < 0.001).

Conclusions

Angiosarcoma increased in incidence and displayed a more severe clinical course, with significantly shorter survival. The strong association between a history of breast cancer 5 years or more prior to the diagnosis of angiosarcoma points to radiotherapy as a contributing factor.

Available only for authorised users

Fletcher CD (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48(1):3–12. https://doi.org/10.1111/j.1365-2559.2005.02284.xCrossRefPubMed

Jo VY, Fletcher CD (2014) WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 46(2):95–104. https://doi.org/10.1097/pat.0000000000000050CrossRefPubMed

Fletcher CD (2014) The evolving classification of soft tissue tumours—an update based on the new 2013 WHO classification. Histopathology 64(1):2–11. https://doi.org/10.1111/his.12267CrossRefPubMed

Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353(7):701–711. https://doi.org/10.1056/NEJMra041866CrossRefPubMed

Burningham Z, Hashibe M, Spector L, Schiffman JD (2012) The epidemiology of sarcoma. Clin Sarcoma Res 2(1):14. https://doi.org/10.1186/2045-3329-2-14CrossRefPubMedPubMedCentral

Chen C, Borker R, Ewing J, Tseng WY, Hackshaw MD, Saravanan S, Dhanda R, Nadler E (2014) Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma 2014:145764. https://doi.org/10.1155/2014/145764CrossRefPubMedPubMedCentral

Corey RM, Swett K, Ward WG (2014) Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med 3(5):1404–1415. https://doi.org/10.1002/cam4.288CrossRefPubMedPubMedCentral

Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc'h M, Istier L, Chalabreysse P, Muller C, Alberti L, Bringuier PP, Scoazec JY, Schott AM, Bergeron C, Cellier D, Blay JY, Ray-Coquard I (2011) Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE 6(8):e20294. https://doi.org/10.1371/journal.pone.0020294CrossRefPubMedPubMedCentral

Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, Ness KK, Casanova M, Spunt SL (2011) Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer 57(6):943–949. https://doi.org/10.1002/pbc.23252CrossRefPubMedPubMedCentral

10.

Honore C, Meeus P, Stoeckle E, Bonvalot S (2015) Soft tissue sarcoma in France in 2015: epidemiology, classification and organization of clinical care. J Visceral Surg 152(4):223–230. https://doi.org/10.1016/j.jviscsurg.2015.05.001CrossRef

11.

Mastrangelo G, Fadda E, Cegolon L, Montesco MC, Ray-Coquard I, Buja A, Fedeli U, Frasson A, Spolaore P, Rossi CR (2010) A European project on incidence, treatment, and outcome of sarcoma. BMC Public Health 10:188. https://doi.org/10.1186/1471-2458-10-188CrossRefPubMedPubMedCentral

12.

Zahm SH, Fraumeni JF Jr (1997) The epidemiology of soft tissue sarcoma. Semin Oncol 24(5):504–514PubMed

13.

Virtanen A, Pukkala E, Auvinen A (2006) Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer 118(4):1017–1021. https://doi.org/10.1002/ijc.21456CrossRefPubMed

14.

Pencavel T, Allan CP, Thomas JM, Hayes AJ (2011) Treatment for breast sarcoma: a large, single-centre series. Eur J Surg Oncol 37(8):703–708. https://doi.org/10.1016/j.ejso.2011.04.006CrossRefPubMed

15.

Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49(3):684–695. https://doi.org/10.1016/j.ejca.2012.09.011CrossRefPubMed

16.

Lim SZ, Ng CCY, Rajasegaran V, Guan P, Selvarajan S, Thike AA, Nasir NDBM, Koh VCY, Tan BKT, Ong KW, Teh BT, Tan PH (2019) Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours. Breast Cancer Res Treat 174(2):365–373. https://doi.org/10.1007/s10549-018-5067-5CrossRefPubMed

17.

Rubino C, Shamsaldin A, Le MG, Labbe M, Guinebretiere JM, Chavaudra J, de Vathaire F (2005) Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 89(3):277–288. https://doi.org/10.1007/s10549-004-2472-8CrossRefPubMed

18.

Seinen JM, Styring E, Verstappen V, Vult von Steyern F, Rydholm A, Suurmeijer AJ, Hoekstra HJ (2012) Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol 19(8):2700–2706. https://doi.org/10.1245/s10434-012-2310-xCrossRefPubMedPubMedCentral

19.

Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T (2013) Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat 140(1):207–211. https://doi.org/10.1007/s10549-013-2621-zCrossRefPubMed

20.

Cui L, Zhang J, Zhang X, Chang H, Qu C, Zhang J, Zhong D (2015) Angiosarcoma (Stewart-Treves syndrome) in postmastectomy patients: report of 10 cases and review of literature. Int J Clin Exp Pathol 8(9):11108–11115PubMedPubMedCentral

21.

Rutqvist LE (1996) Breast cancer. Acta Oncol (Stockholm, Sweden) 35(Suppl 7):54–63. https://doi.org/10.3109/02841869609101663CrossRef

22.

Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol (Stockholm, Sweden) 48(1):27–33. https://doi.org/10.1080/02841860802247664CrossRef

23.

Killander F, Karlsson P, Anderson H, Mattsson J, Holmberg E, Lundstedt D, Holmberg L, Malmström P (2016) No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish breast cancer group randomised trial, SweBCG 91 RT. Eur J Cancer 67:57–65. https://doi.org/10.1016/j.ejca.2016.08.001CrossRefPubMed

24.

Wang XY, Jakowski J, Tawfik OW, Thomas PA, Fan F (2009) Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 13(3):147–150. https://doi.org/10.1016/j.anndiagpath.2009.02.001CrossRefPubMed

25.

Hodgson NC, Bowen-Wells C, Moffat F, Franceschi D, Avisar E (2007) Angiosarcomas of the breast: a review of 70 cases. Am J Clin Oncol 30(6):570–573. https://doi.org/10.1097/COC.0b013e3181131d62CrossRefPubMed

26.

Abbott R, Palmieri C (2008) Angiosarcoma of the breast following surgery and radiotherapy for breast cancer. Nat Clin Pract Oncol 5(12):727–736. https://doi.org/10.1038/ncponc1242CrossRefPubMed

27.

Cabete J, Lencastre A, Fidalgo A, Lobo L, Joao A, Serrao V (2014) Postradiation cutaneous angiosarcoma of the breast: a diagnosis to keep in mind. Breast J 20(1):89–90. https://doi.org/10.1111/tbj.12215CrossRefPubMed

28.

Depla AL, Scharloo-Karels CH, de Jong MA, Oldenborg S, Kolff MW, Oei SB, van Coevorden F, van Rhoon GC, Baartman EA, Scholten RJ, Crezee J, van Tienhoven G (2014) Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer 50(10):1779–1788. https://doi.org/10.1016/j.ejca.2014.03.002CrossRefPubMed

29.

Ghareeb ER, Bhargava R, Vargo JA, Florea AV, Beriwal S (2014) Primary and radiation-induced breast angiosarcoma: clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. Am J Clin Oncol. https://doi.org/10.1097/coc.0000000000000077CrossRef

30.

Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE (2013) Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20(4):1267–1274. https://doi.org/10.1245/s10434-012-2755-yCrossRefPubMed

31.

Mito JK, Mitra D, Barysauskas CM, Marino-Enriquez A, Morgan EA, Fletcher CDM, Raut CP, Baldini EH, Doyle LA (2019) A comparison of outcomes and prognostic features for radiation-associated angiosarcoma of the breast and other radiation-associated sarcomas. Int J Radiat Oncol Biol Phys 104(2):425–435. https://doi.org/10.1016/j.ijrobp.2019.01.082CrossRefPubMed

32.

Taffurelli M, Pellegrini A, Meattini I, Orzalesi L, Tinterri C, Roncella M, Terribile D, Caruso F, Tazzioli G, Pollini G, Friedman D, Mariotti C, Cianchetti E, Cabula C, Thomas R, Cedolini C, Rovera F, Grassi M, Lucani G, Cappella A, Bortul M, Stacul G, Scarabeo F, Procaccini E, Galimberti V (2019) Secondary breast angiosarcoma: a multicentre retrospective survey by the national Italian association of breast surgeons (ANISC). Breast 45:56–60. https://doi.org/10.1016/j.breast.2019.02.011CrossRefPubMed

33.

Merfeld E, Gabani P, Spraker MB, Zoberi I, Kim H, Van Tine B, Chrisinger J, Michalski JM (2019) Clinical outcomes and prognostic features of angiosarcoma: significance of prior radiation therapy. Clin Oncol (R Coll Radiol) 31(4):232–241. https://doi.org/10.1016/j.clon.2019.01.006CrossRef

34.

Yin M, Wang W, Drabick JJ, Harold HA (2017) Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer 17(1):295. https://doi.org/10.1186/s12885-017-3292-7CrossRefPubMedPubMedCentral

35.

Salminen SH, Sampo MM, Bohling TO, Tuomikoski L, Tarkkanen M, Blomqvist CP (2018) Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma. Cancer Med 7(9):4825–4835. https://doi.org/10.1002/cam4.1698CrossRefPubMedPubMedCentral

Title: Sarcoma of the breast: breast cancer history as etiologic and prognostic factor—A population-based case–control study
Authors: Fredrik Karlsson
Fredrik Granath
Karin E. Smedby
Jan Zedenius
Robert Bränström
Inga-Lena Nilsson
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Sarcoma
Radiotherapy
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05802-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)

Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Diagnostic workup of early-stage breast cancer: can we choose more wisely?

Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method

Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants

Keynote webinar | Spotlight on antibody–drug conjugates in cancer